Metabolic TME remodeling could be achieved by exhausting tumor-promoting immune cells and promoting glycolysis in newly generated T cells, through a combination of inhibitory immune therapy against CTLA-4 (which diminish Treg cells) and metabolism inhibitors, with the consequent increase of effector T cells [126]. The gene discussed is CTLA4; the disease is neoplasm.